Oxadiazole inhibitors of leukotriene production

US8658661B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Alessandra Bartolozzi · Norwalk, US
• Todd Bosanac · New Milford, US
• Zhidong Chen · New Milford, US
• Stéphane De Lombaert · Madison, US
• John D. Huber · New York, US
• Ho Yin Lo · Bethel, US
• Pui Leng Loke · Abingdon, GB
• Weimin Liu · Sandy Hook, US
• Tina Morwick · New Milford, US
• Alan Olague · Shelton, US
• Doris Riether · Biberach an der Riß, DE
• Heather Tye · Abingdon, GB
• Lifen Wu · New Milford, US
• Renee M. Zindell · New Milford, US

Key dates

• Filing date: Aug 12, 2011
• Grant date: Feb 25, 2014
• Expiry date: Nov 3, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D498/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compound of formula (I):or pharmaceutically acceptable salts thereof, wherein R1-R5 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.